NeoGenomics to Leverage Thermo Fisher Sequencing Solution in Myeloid Cancer Study
NeoGenomics will use Thermo Fisher Scientific’s next-generation sequencing solution in a pharma-sponsored Phase 1 study of myeloid cancer.
Read MorePosted by Andy Lundin | Dec 28, 2021 | Cancer, Sequencing Systems |
NeoGenomics will use Thermo Fisher Scientific’s next-generation sequencing solution in a pharma-sponsored Phase 1 study of myeloid cancer.
Read MorePosted by Chris Wolski | Sep 8, 2021 | Molecular Diagnostic Analyzers |
Mission Bio has announced two key improvements to the core capabilities of its Tapestri Platform for hematologic oncology (heme-onc) research.
Read MorePosted by Melanie Hamilton-Basich | Jul 27, 2021 | Cancer |
St. Jude Children’s Research Hospital investigators have demonstrated that comprehensive genomic sequencing of all pediatric cancer patients is feasible and essential to capitalize on the lifesaving potential of precision medicine.
Read MorePosted by Chris Wolski | Jul 12, 2021 | Covid 19 |
Through much of 2020, SARS-CoV-2 accumulated mutations at a slow and steady rate, but more variants have emerged with new pathogenic traits.
Read MorePosted by Chris Wolski | Jun 24, 2021 | Company News |
A trio of cutting-edge companies have announced a collaboration that will enable nearly instant medical test results.
Read More